Perforación intestinal en paciente COVID-19 en tratamiento con tocilizumab y corticoides. A propósito de un caso
- 29 April 2020
- journal article
- editorial
- Published by Elsevier BV in Cirugía Española
- Vol. 99 (2), 156-157
- https://doi.org/10.1016/j.ciresp.2020.04.030
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Abdominal and testicular pain: An atypical presentation of COVID-19The American Journal of Emergency Medicine, 2020
- COVID-19 Outbreak and Surgical PracticeAnnals of Surgery, 2020
- Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2020
- Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data SourcesRheumatology and Therapy, 2016
- Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDsAnnals Of The Rheumatic Diseases, 2016
- Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic TreatmentsArthritis & Rheumatology, 2016
- Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in JapanThe Journal of Rheumatology, 2015
- Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structuArthritis & Rheumatism, 2011
- Integrated safety in tocilizumab clinical trialsArthritis Research & Therapy, 2011
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trialAnnals Of The Rheumatic Diseases, 2008